The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine

Chen, Peng; Zhang, Jie; Wang, Chen; Chai, Yang; Wu, Anguo; Huang, Ning-yu; Wang, Long

doi:10.1016/j.phymed.2022.154044

Cited by 24 publications

(14 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herbal products have gradually gained acceptance in treating neurodegenerative diseases for their multi-functional characteristic with relatively fewer adverse effects ( Wahid et al, 2020 ; Gregory et al, 2021 ; Wang et al, 2021 ). Herbal medicines have been applied to treat PD ( Chen et al, 2022 ; Sharma et al, 2022 ; Zahedipour et al, 2022 ), and GBE has proven efficacy. G. biloba , a medicinal plant belonging to the Ginkgoaceae family, is considered the oldest tree alive in the world ( Chen et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease

Yan

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease with a fast-growing prevalence. Developing disease-modifying therapies for PD remains an enormous challenge. Current drug treatment will lose efficacy and bring about severe side effects as the disease progresses. Extracts from Ginkgo biloba folium (GBE) have been shown neuroprotective in PD models. However, the complex GBE extracts intertwingled with complicated PD targets hinder further drug development. In this study, we have pioneered using single-nuclei RNA sequencing data in network pharmacology analysis. Furthermore, high-throughput screening for potent drug-target interaction (DTI) was conducted with a deep learning algorithm, DeepPurpose. The strongest DTIs between ginkgolides and MAPK14 were further validated by molecular docking. This work should help advance the network pharmacology analysis procedure to tackle the limitation of conventional research. Meanwhile, these results should contribute to a better understanding of the complicated mechanisms of GBE in treating PD and lay the theoretical ground for future drug development in PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease

Yan

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The herbal ingredient Gastrodis Tuber can be beneficial for qi and blood, dispelling wind, resolving phlegm, and activating the blood and making it clear (Lin et al, 2019). Based on a previous study, Gastrodis Tuber inhibits oxidative stress and apoptosis in 1-methyl-4-phenlypyridinum and stimulates SH-SY5Y cells by the upregulation of heme oxygenase through the p38 MAPK/Nrf2 pathway (Chen et al, 2022). Thus, using it to treat SD symptoms, as well as "stirring wind" and "blood stasis," may be beneficial.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of herbal medicine treatment based on syndrome differentiation for Parkinson’s disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials

et al. 2023

View full text Add to dashboard Cite

Background: Parkinson’s disease (PD), the second most common progressive neurodegenerative disease, causes heterogeneous clinical symptoms. Patients experience a range of motor and non-motor symptoms, and personalized diagnosis and treatment are needed. In traditional East Asian medicine, syndrome differentiation (SD) is a diagnostic approach for customized therapy that uses a comprehensive analysis and varies for the same disease. We aimed to evaluate the efficacy of herbal medicine (HM) prescribed according to the SD of PD.Methods: Ten electronic databases were searched from inception to August 2021 without language limitations. All randomized controlled trials (RCTs) involving HM for SD of PD were included. Assessment of Cochrane's risk of bias and meta-analysis and Grading of Recommendations Assessment, Development, and Evaluation was also performed. Effect measurement was summarized using the mean difference (MD) with 95% confidence interval, through a meta-analysis.Results: Thirteen RCTs involving 843 participants were included. The overall risk of bias was either low or unclear. Compared with the placebo, a combined therapy of HM and Western medicine (WM) significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) (MD = −8.03, [−10.27, −5.79], p < 0.00001; I2 = 0%) and was more beneficial, as assessed using the UPDRS (I–III), the Parkinson’s Disease Questionnaire-39, and the Non-Motor Symptoms Scale. Adverse events did not differ between the groups.Conclusion: The findings suggest that the combined treatment of WM and HM based on SD diagnosis has additional benefits in PD treatment. However, the methodological quality of the included RCTs was suboptimal. Nevertheless, this systematic review is the first to investigate the efficacy of HM treatment according to the SD diagnosis in PD. The clinically meaningful improvement in HM according to SD in PD needs to be tested in further studies with rigorous designs and longer follow-up periods.Systematic Review Registration: [https://inplasy.com/inplasy-2021-10-0020/], identifier [INPLASY2021100020].

show abstract

“…In the treatment of CNS diseases, TCM not only adheres to the traditional wisdom accumulated over centuries but also gradually reveals its unique contributions in the field of modern medical research. [ 5 , 6 ] However, traditional formulations, primarily in the form of decoctions, are inconvenient both in preparation and administration and exhibit notable instability. On the research front, the complex and diverse composition of traditional Chinese herbal compounds, along with their unclear mechanisms of action, poses challenges.…”

Section: Tcm For Cns Diseasesmentioning

confidence: 99%

“…[ 2 ] To date, TCM and the active ingredients contained in these classical prescriptions have been used for the clinical treatment of diseases related to CNS damage, such as stroke, Parkinson's disease, or Alzheimer's disease. [ 3 , 4 , 5 , 6 ] Modern research has also confirmed that TCM and the effective components contained in the compound preparations can improve cerebral microcirculation disorders against damage to the nervous system and neurons. [ 2 ] However, conventional water‐soluble TCM decoctions have insufficient membrane permeability and low bioavailability owing to insufficient lipid solubility and inappropriate molecular size, [ 7 , 8 ] and thus cannot effectively penetrate the blood‐brain barrier (BBB) and reach effective concentrations in the brain tissue.…”

Section: Introductionmentioning

confidence: 99%

Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine

Li,

Long,

Ding

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Traditional Chinese Medicine (TCM) is widely used in clinical practice to treat diseases related to central nervous system (CNS) damage. However, the blood‐brain barrier (BBB) constitutes a significant impediment to the effective delivery of TCM, thus substantially diminishing its efficacy. Advances in nanotechnology and its applications in TCM (also known as nano‐TCM) can deliver active ingredients or components of TCM across the BBB to the targeted brain region. This review provides an overview of the physiological and pathological mechanisms of the BBB and systematically classifies the common TCM used to treat CNS diseases and types of nanocarriers that effectively deliver TCM to the brain. Additionally, drug delivery strategies for nano‐TCMs that utilize in vivo physiological properties or in vitro devices to bypass or cross the BBB are discussed. This review further focuses on the application of nano‐TCMs in the treatment of various CNS diseases. Finally, this article anticipates a design strategy for nano‐TCMs with higher delivery efficiency and probes their application potential in treating a wider range of CNS diseases.

show abstract

The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine

Cited by 24 publications

References 165 publications

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease

Efficacy of herbal medicine treatment based on syndrome differentiation for Parkinson’s disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials

Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine

Contact Info

Product

Resources

About